Key result
Early catheter ablation at ICD implantation cuts VT recurrence, CV hospitalization, or death ~42%.
Why the study?
First-line catheter ablation for VT at the time of ICD implantation has not been adopted into guidelines, and prospective data in nonischemic cardiomyopathy were needed.
Does first-line catheter ablation plus an ICD reduce the composite of VT recurrence, cardiovascular hospitalization, or death in patients with cardiomyopathy and monomorphic VT compared to conventional medical therapy plus an ICD?
RCT (n=180)
1:1
Yes
Does first-line catheter ablation plus an ICD reduce the composite of VT recurrence, cardiovascular hospitalization, or death in patients with cardiomyopathy and monomorphic VT compared to conventional medical therapy plus an ICD?
First-line catheter ablation performed at the time of ICD implantation significantly reduces the composite of VT recurrence, cardiovascular hospitalization, or death in patients with cardiomyopathy and monomorphic VT.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Congrats to @DrRoderickTung and team for PAUSE-SCD LBCT showing benefit of first-line VT ablation for reducing recurrent VT. Consistent with results of other trials on preventive approach to VT ablation but now with added inclusion of non-MI VT etiologies.”
“The investigators of PAUSE-SCD demonstrated that CA as first-line therapy reduced recurrent VT and appropriate ICD therapies. Both PARTITA and PAUSE-SCD demonstrated favorable outcomes in regards to VT recurrence but failed to show any reduction in mortality.”
“Ablation has historically been viewed as a palliative, last-resort strategy and bringing it upfront as concurrent therapy with ICD implantation is a potentially meaningful paradigm shift. It is also the first to include patients with VT without prior myocardial infarction as well as the first to include more contemporary procedural strategies, such as high-resolution mapping and epicardial approaches. We hope that these results will influence future guidelines that are trending toward earlier use of catheter ablation over medical therapy in the course of patient treatment.”
Supports first-line VT ablation at ICD implantation in cardiomyopathy; extends evidence to nonischemic patients and challenges guideline omission.
Background: Catheter ablation as first-line therapy for ventricular tachycardia (VT) at the time of implantable cardioverter defibrillator (ICD) implantation has not been adopted into clinical guidelines. Also, there is an unmet clinical need to prospectively examine the role of VT ablation in patients with nonischemic cardiomyopathy, an increasingly prevalent population that is referred for advanced therapies globally. Methods: We conducted an international, multicenter, randomized controlled trial enrolling 180 patients with cardiomyopathy and monomorphic VT with an indication for ICD implantation to assess the role of early, first-line ablation therapy. A total of 121 patients were randomly assigned (1:1) to ablation plus an ICD versus conventional medical therapy plus an ICD. Patients who refused ICD (n=47) were followed in a prospective registry after stand-alone ablation treatment. The primary outcome was a composite end point of VT recurrence, cardiovascular hospitalization, or death. Results: Randomly assigned patients had a mean age of 55 years (interquartile range, 46–64) and left ventricular ejection fraction of 40% (interquartile range, 30%–49%); 81% were male. The underlying heart disease was ischemic cardiomyopathy in 35%, nonischemic cardiomyopathy in 30%, and arrhythmogenic cardiomyopathy in 35%. Ablation was performed a median of 2 days before ICD implantation (interquartile range, 5 days before to 14 days after). At 31 months, the primary outcome occurred in 49.3% of the ablation group and 65.5% in the control group (hazard ratio, 0.58 [95% CI, 0.35–0.96]; P =0.04). The observed difference was driven by a reduction in VT recurrence in the ablation arm (hazard ratio, 0.51 [95%CI, 0.29–0.90]; P =0.02). A statistically significant reduction in both ICD shocks (10.0% versus 24.6%; P =0.03) and antitachycardia pacing (16.2% versus 32.8%; P =0.04) was observed in patients who underwent ablation compared with control. No differences in cardiovascular hospitalization (32.0% versus. 33.7%; hazard ratio, 0.82 [95% CI, 0.43–1.56]; P =0.55) or mortality (8.9% versus 8.8%; hazard ratio, 1.40 [95% CI, 0.38–5.22]; P =0.62]) were observed. Ablation-related complications occurred in 8.3% of patients. Conclusions: Among patients with cardiomyopathy of varied causes, early catheter ablation performed at the time of ICD implantation significantly reduced the composite primary outcome of VT recurrence, cardiovascular hospitalization, or death. These findings were driven by a reduction in ICD therapies. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02848781.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an RCT in Cardiomyopathy and monomorphic ventricular tachycardia (n=180). Catheter ablation plus an ICD vs. Conventional medical therapy plus an ICD was evaluated on Composite of VT recurrence, cardiovascular hospitalization, or death (HR 0.58, 95% CI 0.35-0.96, p=0.04). Early catheter ablation at the time of ICD implantation reduced the composite of VT recurrence, cardiovascular hospitalization, or death.
Synapse has enriched 10 related papers. Consider them for comparative context: